Spotlight On... Pfizer joins Human Vaccines Project; PATH to open 'Center for Vaccine Innovation and Access' with $11M Gates Foundation grant; Cadila shares suffer on WHO plant inspection report; and more…

FDA

Pfizer ($PFE) enlisted in the Human Vaccines Project, joining an influential group of peers and research institutions setting out to "decode the human immune system." Founded at the International AIDS Vaccine Institute, the Human Vaccines Project so far has participation from a broad range of pharma partners and academic institutions, hoping that knowledge gained through the partnership will help in the development of vaccines against infectious diseases, cancer, flu, dengue and other targets. In addition to Pfizer, participants so far are Regeneron ($REGN), GlaxoSmithKline ($GSK), AstraZeneca's ($AZN) MedImmune, Sanofi Pasteur, Janssen, among others. Release

> Seattle-based nonprofit PATH plans to open a "Center for Vaccine Innovation and Access," with initial funding in the amount of $11 million coming from the Bill & Melinda Gates Foundation, according to reports. Release | More

> WHO regulators noted "several major deviations" at a Cadila Healthcare vaccine plant in India following a recent inspection, sending the company's shares downward. Report

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

> Soligenix netted $660,000 in NIAID funding to advance regulatory interactions on its heat stable ricin vaccine. Release

> Hyderabad-based Biological E received a Rs895 crore ($134 million) order from the country's health ministry to provide its 5-in-1 liquid pentavalent vaccine for the universal vaccination program. Report

Read more on

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.